Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05605548 · ClinicalTrials.gov registry record · Early Phase 1
Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)
A Early Phase 1 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT05605548: Clinical Trial Early Phase 1 study, sponsored by Virginia Commonwealth University.
NCT05605548 is a Early Phase 1 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 4 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05605548, a Early Phase 1 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that has shown promise in improving cardiovascular outcomes in similar populations. Thus the purpose of this study is to test if MitoQ can improve cardiovascular health in COPD.
Primary Outcome
Flow-mediated dilation will be used to measure vasodilation in the brachial artery
Interventions
- OTHER Placebo
- DRUG MitoQ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-02-16 |
| Est. Completion | 2024-07-30 |
| Phase | Early Phase 1 |
Why NCT05605548 stopped before completion
NCT05605548 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05605548 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05605548 about?
NCT05605548 is a clinical study titled "Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)". Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that has shown promise in i...
What is the current status of trial NCT05605548?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2023-02-16. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT05605548?
The interventions under investigation include: Placebo (OTHER), MitoQ (DRUG).
Who is sponsoring clinical trial NCT05605548?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05605548's enrollment target sits among peer trials
4 1921st of 2000 higher than 53 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI